RECEIVED CENTRAL FAX CENTER

OCT 2 6 2004

PTO/\$B/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paper Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

			Application Number		09/486,839
TRANSMITTAL			Filing Date		March 1, 2000 (03/01/2000)
FORM			First Named Inventor		Achari, Raja G.
(to be used for all correspondence after initial filing)		Art Unit		1617	
(10 be used for all correspondence one when any		Examiner Name		Shaojia A. Jiang	
		Legal Instruments Examiner (LIE)		Coralia Betancourt	
Total Number of Pages in This Submission 4		4	Attorney Docket Number		97-01US2
ENCLOSURES (check all that apply)					
X Amendm Non-Corr After Affice Extension Express Informatic Document Incomplete Response Resp	nemittal Form Attached ent / Reply to Notice of opliant Amendment r Final davits/declaration(s) n of Time Request Abandonment Request on Disclosure Statement Copy of Priority ot(s) e to Missing Parts/ the Application sponse to Missing Parts er 37 CFR 1.52 or 1.53		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Apolication Power of Attorney, Revocation Change of Correspondence Addres Terminal Disclaimer Request for Refund CD, Number of CD(s)	S X Revisiprope	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): ed Amendments to the Claims with the ristatus identifier.
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm or Individual Signature Date	Nastech Pharmacautical Company Inc. by Paul G. Lunn, Patent Counsel				
CERTIFICATE OF FACSIMILE TRANSMISSION 1 hereby certify that this correspondence is being transmitted by facsimile to the USPTO to the fax number: 703-872-8306 on this date:					
I hereby certify that this correspondence is being transmitted by fa Sent by Facelmile by: Leslie Kodiah, signature:			facalmile to the USPTO to the fax num	nper: 703-87	2-8306 on this date: October 26, 2004
Type or printed Leslle M. Kodish				D-1-	O-tohor 26, 2004
Signature	Jeslee M. Kodih		0 ch h	Date	October 26, 2004

This collection of information is required by 37 CFR 1.5. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, cell 1-800-PTO-9189 (1-800-786-9199) and select option 2.

NASTECH PHARM RECEIVED CENTRAL FAX CENTER

OCT 2 6 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Achari, et al.

U.S. Application Serial No.: 09/486,839

Filed: 3/1/2000

Title: INTRANASAL FORMULATIONS CONTAINING

SCOPOLAMINE AND METHOD OF TREATING

MOTION SICKNESS

Group Art Unit: 1617

Examiner: Shaojia A. Jiang, Ph.D. Legal Instruments Examiner (LIE)

Corolia Betancourt

Date: October 26, 2004

Attorney Docket No.: 97-01US2 (please update our case number)

United States Department of Commerce United States Patent and Trademark Office Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 VIA FACSIMILE TO: (703) 872-9306

AMENDMENT OF THE CLAIMS

Dear Dr. Jiang or Corolia Betancourt:

This is in response to the Office Action, Notice of Non-Compliant Amendment, dated October 15, 2004, for the above-referenced application. Attached is the corrected section of the non-compliant amendment. The status of every claim in now indicated after its claim number using the status identifiers.

Claims 23-26 are being prosecuted, and new claims 27 and 28 have been added.

Applicants respectfully traverse the rejection. Please amend the claims of the application as follows: